Pasar al contenido principal

MODULACION DE LA RESPUESTA IMNUNE INNATA POR ISG15 Y SU IMPACTO EN LA RESPUESTA INMUNE ADAPTATIVA

PID2020-117425RB-C21

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD AUTONOMA DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Lipin-2 regulates the antiviral and anti-inflammatory responses to interferon

  • Pablo, Nagore de
  • Meana, Clara
  • Martínez‐García, Javier
  • Martínez‐Vicente, Pablo
  • Albert, Manuel
  • Guerra, Susana
  • Angulo, Ana
  • Balsinde, Jesús
  • Balboa, María A.
Interferons (IFN) are crucial antiviral and immunomodulatory cytokines that exert their function through the regulation of a myriad of genes, many of which are not yet characterized. Here, we reveal that lipin‐2, a phosphatidic acid phosphatase whose mutations produce an autoinflammatory syndrome known as Majeed syndrome in humans, is regulated by IFN in a STAT‐1‐dependent manner. Lipin‐2 inhibits viral replication both in vitro and in vivo. Moreover, lipin‐2 also acts as a regulator of inflammation in a viral context by reducing the signaling through TLR3 and the generation of ROS and release of mtDNA that ultimately activate the NLRP3 inflammasome. Inhibitors of mtDNA release from mitochondria restrict IL‐1β production in lipin‐2‐deficient animals in a model of viral infection. Finally, analyses of databases from COVID‐19 patients show that LPIN2 expression levels negatively correlate with the severity of the disease. Overall, these results uncover novel regulatory mechanisms of the IFN response driven by lipin‐2 and open new perspectives for the future management of patients with LPIN2 mutations., This work was supported by the Spanish Ministry of Economy, Industry, and Competitiveness (grant SAF2016‐80883‐R), Spanish Ministry of Science and Innovation (MICIN/AEI/https://doi.org/10.13039/501100011033; grants PID2019‐105989RB‐I00; PID2020‐116918RB‐100; and PID2020‐117425RB‐C21), CIBERDEM‐ISCIII (grant CB07/08/0004), and the Regional Government of Castile and Leon (grant CSI141P20, cofinanced by the European Union through the European Regional Development Fund, “A Way of Making Europe”). N. de Pablo and J. Martínez‐García were supported by predoctoral fellowships from the Spanish Ministry of Science and Innovation (FPU14‐02879) and the Regional Government of Castile and Leon (E‐47‐2021‐0015435), respectively. Instituto de Biología y Genética Molecular is a research center partnered between the Spanish National Research Council (CSIC) and the University of Valladolid., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Unveiling the Multifaceted Roles of ISG15: From Immunomodulation to Therapeutic Frontiers

  • Álvarez, Enrique
  • Falqui, Michela
  • Sin, Laura
  • McGrail, Joseph Patrick
  • Perdiguero, Beatriz
  • Coloma, Rocío
  • Marcos-Villar, Laura
  • Tárrega, Céline
  • Esteban, Mariano
  • Gómez, Carmen E.
  • Guerra, Susana
The Interferon Stimulated Gene 15 (ISG15), a unique Ubiquitin-like (Ubl) modifier exclusive to vertebrates, plays a crucial role in the immune system. Primarily induced by interferon (IFN) type I, ISG15 functions through diverse mechanisms: (i) covalent protein modification (ISGylation); (ii) non-covalent intracellular action; and (iii) exerting extracellular cytokine activity. These various roles highlight its versatility in influencing numerous cellular pathways, encompassing DNA damage response, autophagy, antiviral response, and cancer-related processes, among others. The well-established antiviral effects of ISGylation contrast with its intriguing dual role in cancer, exhibiting both suppressive and promoting effects depending on the tumour type. The multifaceted functions of ISG15 extend beyond intracellular processes to extracellular cytokine signalling, influencing immune response, chemotaxis, and anti-tumour effects. Moreover, ISG15 emerges as a promising adjuvant in vaccine development, enhancing immune responses against viral antigens and demonstrating efficacy in cancer models. As a therapeutic target in cancer treatment, ISG15 exhibits a double-edged nature, promoting or suppressing oncogenesis depending on the tumour context. This review aims to contribute to future studies exploring the role of ISG15 in immune modulation and cancer therapy, potentially paving the way for the development of novel therapeutic interventions, vaccine development, and precision medicine., This research was supported by Spanish Ministry of Science and Innovation (MCIN)/Spanish State Research Agency, state secretary of R + D and FEDER/FSE grants: SAF2017-88089-R and PDC2021-121307-I00 to S.G. and M.E., PID2020-117425RB-C21 to S.G. and PID2020-117425RB-C22 to C.E.G., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

An MVA-based vector expressing cell-free ISG15 increases IFN-I production and improves HIV-1-specific CD8 T cell immune responses

  • Falqui, Michela
  • Perdiguero, Beatriz
  • Coloma, Rocío
  • Albert, Manuel
  • Marcos-Villar, Laura
  • McGrail, Joseph Patrick
  • Sorzano, Carlos Óscar S.
  • Esteban, Mariano
  • Gómez, Carmen Elena
  • Guerra, Susana
The human immunodeficiency virus (HIV), responsible of the Acquired Immune Deficiency Syndrome (AIDS), continues to be a major global public health issue with any cure or vaccine available. The Interferon-stimulated gene 15 (ISG15) encodes a ubiquitin-like protein that is induced by interferons and plays a critical role in the immune response. ISG15 is a modifier protein that covalently binds to its targets via a reversible bond, a process known as ISGylation, which is the best-characterized activity of this protein to date. However, ISG15 can also interact with intracellular proteins via non-covalent binding or act as a cytokine in the extracellular space after secretion. In previous studies we proved the adjuvant effect of ISG15 when delivered by a DNA-vector in heterologous prime-boost combination with a Modified Vaccinia virus Ankara (MVA)-based recombinant virus expressing HIV-1 antigens Env/Gag-Pol-Nef (MVA-B). Here we extended these results evaluating the adjuvant effect of ISG15 when expressed by an MVA vector. For this, we generated and characterized two novel MVA recombinants expressing different forms of ISG15, the wild-type ISG15GG (able to perform ISGylation) or the mutated ISG15AA (unable to perform ISGylation). In mice immunized with the heterologous DNA prime/MVA boost regimen, the expression of the mutant ISG15AA from MVA-Δ3-ISG15AA vector in combination with MVA-B induced an increase in the magnitude and quality of HIV-1-specific CD8 T cells as well as in the levels of IFN-I released, providing a better immunostimulatory activity than the wild-type ISG15GG. Our results confirm the importance of ISG15 as an immune adjuvant in the vaccine field and highlights its role as a potential relevant component in HIV-1 immunization protocols., This research was supported by the Spanish State Research Agency Ministry of Health of Spain, State secretary of R+D and FEDER/FSE, SAF-2017-88089-R, PDC2021-121307-I00 PID2020- 117425RB-C21 to SG and PID2020-117425RB-C22 to CG; by CIBER consortium, Thematic Area in Infectious Diseases: CIBERINFEC (CB21/13/00108) to CG; by Red Temática de Investigación Cooperativa en Salud: Red Española de Investigación en Sida (RIS) RD16/0025/0014 and in part by European HIV Vaccine Alliance (EHVA) grant ID: 681032 to ME., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

B and T Cell Bi-Cistronic Multiepitopic Vaccine Induces Broad Immunogenicity and Provides Protection Against SARS-CoV-2

  • Perdiguero, Beatriz
  • Álvarez, Enrique
  • Marcos-Villar, Laura
  • Sin, Laura
  • López-Bravo, María
  • Valverde, José Ramón
  • Sorzano, Carlos Óscar S.
  • Falqui, Michela
  • Coloma, Rocío
  • Esteban, Mariano
  • Guerra, Susana
  • Gómez, Carmen E.
[Background]: The COVID-19 pandemic, caused by SARS-CoV-2, has highlighted the need for vaccines targeting both neutralizing antibodies (NAbs) and long-lasting cross-reactive T cells covering multiple viral proteins to provide broad and durable protection against emerging variants., [Methods]: To address this, here we developed two vaccine candidates, namely (i) DNA-CoV2-TMEP, expressing the multiepitopic CoV2-TMEP protein containing immunodominant and conserved T cell regions from SARS-CoV-2 structural proteins, and (ii) MVA-CoV2-B2AT, encoding a bi-cistronic multiepitopic construct that combines conserved B and T cell overlapping regions from SARS-CoV-2 structural proteins., [Results]: Both candidates were assessed in vitro and in vivo demonstrating their ability to induce robust immune responses. In C57BL/6 mice, DNA-CoV2-TMEP enhanced the recruitment of innate immune cells and stimulated SARS-CoV-2-specific polyfunctional T cells targeting multiple viral proteins. MVA-CoV2-B2AT elicited NAbs against various SARS-CoV-2 variants of concern (VoCs) and reduced viral replication and viral yields against the Beta variant in susceptible K18-hACE2 mice. The combination of MVA-CoV2-B2AT with a mutated ISG15 form as an adjuvant further increased the magnitude, breadth and polyfunctional profile of the response., [Conclusion]: These findings underscore the potential of these multiepitopic proteins when expressed from DNA or MVA vectors to provide protection against SARS-CoV-2 and its variants, supporting their further development as next-generation COVID-19 vaccines., This research was supported by La Caixa Banking Foundation, grant CF01-00008; Spanish Ministry of Science and Innovation (MCIN)/Spanish Research Agency, grants PID2020-117425RB-C21, PID2020-117425RB-C22 and PDC2021-121307-100; Fondo COVID-19, grant COV20/00151 (Spanish Health Ministry and ISCIII); CSIC, grant 2020E84; and Ferrovial donations (to M.E.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Preclinical evaluation of a multi-epitope mRNA vaccine platform for broad and durable SARS-CoV-2 protection

  • Marcos-Villar, Laura
  • Perdiguero, Beatriz
  • Sin, Laura
  • Álvarez, Enrique
  • Flores, Sara
  • Casasnovas, José María
  • Pons, Tirso
  • Sorzano, Carlos Óscar S.
  • Hoyo, Daniel del
  • Lapuhs, Philipp
  • Alonso, María J.
  • Esteban, Mariano
  • Gómez, Carmen E.
Introduction: The emergence of immune-evasive SARS-CoV-2 variants has exposed limitations in the breadth and durability of protection conferred by current Spike-based vaccines, highlighting the need for next-generation approaches targeting conserved viral regions. Here, we describe the design and preclinical evaluation of an optimized multi-epitope vaccine, CoV2-BMEPu. Methods: CoV2-BMEPu was rationally designed using immunological data from SARS-CoV-2 convalescent cohorts, incorporating conserved and immunodominant regions from the Spike (S), Membrane (M) and Nucleocapsid (N) proteins, together with selected receptor-binding domain (RBD) segments associated with broadly neutralizing antibodies. The construct was engineered as a secreted trimeric antigen and delivered as an mRNA vaccine formulated in lipid nanoparticles (LNPs). In vitro expression, innate immune activation, immunogenicity and protective efficacy were evaluated in cell systems and mouse models. Results: mRNA-BMEPu was efficiently expressed in vitro as soluble oligomers and triggered innate immune activation in human macrophages. In C57BL/6 mice, LNP-BMEPu elicited robust binding and neutralizing antibodies against the ancestral virus and antigenically distant Omicron subvariants. Vaccination also induced strong and polyfunctional CD8⁺ T cell and T follicular helper responses that persisted over time. In K18-hACE2 transgenic mice, immunization conferred complete protection against lethal SARS-CoV-2 challenge, with effective control of viral replication and reduced lung inflammation. Discussion: These results support CoV2-BMEPu as a next-generation multi-epitope mRNA vaccine candidate capable of inducing broad, durable and protective immunity against current and emerging SARS-CoV-2 variants. Copyright © 2026 Marcos-Villar, Perdiguero, Sin, Álvarez, Flores, Casasnovas, Pons, Sorzano, del Hoyo, Lapuhs, Alonso, Esteban and Gómez., The author(s) declared that financial support was received for this work and/or its publication. This study was supported by multiple public and private sources. Financial support was provided by La Caixa Banking Foundation (grant CF01-00008), MICIN through the Spanish Research Agency under grants PID2020-117425RB-C21, PID2020-117425RB-C22 and PDC2021-121307-100, as well as by the COVID-19 Fund of the Spanish Health Ministry and Instituto de Salud Carlos III (grant COV20/00151) and CIBERINFEC., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Lipin‐2 regulates the antiviral and anti‐inflammatory responses to interferon

  • de Pablo, Nagore
  • Meana, Clara
  • Martínez-García, Javier
  • Martínez-Vicente, Pablo
  • Albert, Manuel
  • Guerra, Susana
  • Angulo, Ana
  • Balsinde, Jesús
  • Balboa, María A
Abstract Interferons (IFN) are crucial antiviral and immunomodulatory cytokines that exert their function through the regulation of a myriad of genes, many of which are not yet characterized. Here, we reveal that lipin‐2, a phosphatidic acid phosphatase whose mutations produce an autoinflammatory syndrome known as Majeed syndrome in humans, is regulated by IFN in a STAT‐1‐dependent manner. Lipin‐2 inhibits viral replication both in vitro and in vivo. Moreover, lipin‐2 also acts as a regulator of inflammation in a viral context by reducing the signaling through TLR3 and the generation of ROS and release of mtDNA that ultimately activate the NLRP3 inflammasome. Inhibitors of mtDNA release from mitochondria restrict IL‐1β production in lipin‐2‐deficient animals in a model of viral infection. Finally, analyses of databases from COVID‐19 patients show that LPIN2 expression levels negatively correlate with the severity of the disease. Overall, these results uncover novel regulatory mechanisms of the IFN response driven by lipin‐2 and open new perspectives for the future management of patients with LPIN2 mutations.